{"entity":{"type":"insider","cik":"0001868719","url":"/insider/0001868719","json_url":"/insider/0001868719.json","name":"Plavsic Mark","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":6,"n_filings":6,"first":"2022-07-06","last":"2026-02-17","span_basis":"filed_date"},"name_variants":[{"name":"Plavsic Mark","source":"filing","n_filings":6,"first_seen":"2022-07-06","last_seen":"2026-02-17"}],"transactions":[{"id":5943456,"accession":"0001193125-26-055497","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001193125-26-055497","line_url":"/filing/0001193125-26-055497#line-1","is_derivative":false,"issuer_cik":"0001501796","issuer_name":"Aura Biosciences, Inc.","issuer_ticker":"AURA","issuer_name_source":null,"issuer_url":"/issuer/0001501796","owner_cik":"0001868719","owner_name":"Plavsic Mark","owner_display_name":"Plavsic Mark","owner_url":"/insider/0001868719","role":"Officer (Chief Technology Officer)","role_mark":"O","role_mark_label":"Officer (Chief Technology Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Technology Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":15890.0,"shares_display":"15,890","price_per_share":5.05,"price_display":"5.05","price_state":"stated","total_value":80244.5,"total_display":"80,244.50","total_whole":"80,245","shares_owned_after":181397.0,"shares_owned_after_display":"181,397","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-02-17","filed_date":"2026-02-17","scope":"insider"},{"id":4066312,"accession":"0001193125-25-241622","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001193125-25-241622","line_url":"/filing/0001193125-25-241622#line-1","is_derivative":false,"issuer_cik":"0001501796","issuer_name":"Aura Biosciences, Inc.","issuer_ticker":"AURA","issuer_name_source":null,"issuer_url":"/issuer/0001501796","owner_cik":"0001868719","owner_name":"Plavsic Mark","owner_display_name":"Plavsic Mark","owner_url":"/insider/0001868719","role":"Officer (Chief Technology Officer)","role_mark":"O","role_mark_label":"Officer (Chief Technology Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Technology Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":12169.0,"shares_display":"12,169","price_per_share":6.35,"price_display":"6.35","price_state":"stated","total_value":77273.15,"total_display":"77,273.15","total_whole":"77,273","shares_owned_after":197287.0,"shares_owned_after_display":"197,287","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-10-16","filed_date":"2025-10-16","scope":"insider"},{"id":4311703,"accession":"0000950170-25-022655","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000950170-25-022655","line_url":"/filing/0000950170-25-022655#line-1","is_derivative":false,"issuer_cik":"0001501796","issuer_name":"Aura Biosciences, Inc.","issuer_ticker":"AURA","issuer_name_source":null,"issuer_url":"/issuer/0001501796","owner_cik":"0001868719","owner_name":"Plavsic Mark","owner_display_name":"Plavsic Mark","owner_url":"/insider/0001868719","role":"Officer (Chief Technology Officer)","role_mark":"O","role_mark_label":"Officer (Chief Technology Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Technology Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2151.0,"shares_display":"2,151","price_per_share":7.75,"price_display":"7.75","price_state":"stated","total_value":16670.25,"total_display":"16,670.25","total_whole":"16,670","shares_owned_after":209456.0,"shares_owned_after_display":"209,456","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-02-18","filed_date":"2025-02-18","scope":"insider"},{"id":2210015,"accession":"0000950170-24-115150","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000950170-24-115150","line_url":"/filing/0000950170-24-115150#line-1","is_derivative":false,"issuer_cik":"0001501796","issuer_name":"Aura Biosciences, Inc.","issuer_ticker":"AURA","issuer_name_source":null,"issuer_url":"/issuer/0001501796","owner_cik":"0001868719","owner_name":"Plavsic Mark","owner_display_name":"Plavsic Mark","owner_url":"/insider/0001868719","role":"Officer (Chief Technology Officer)","role_mark":"O","role_mark_label":"Officer (Chief Technology Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Technology Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":7383.0,"shares_display":"7,383","price_per_share":9.85,"price_display":"9.85","price_state":"stated","total_value":72722.55,"total_display":"72,722.55","total_whole":"72,723","shares_owned_after":121132.0,"shares_owned_after_display":"121,132","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-10-16","filed_date":"2024-10-16","scope":"insider"},{"id":8034527,"accession":"0001209191-23-002976","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-23-002976","line_url":"/filing/0001209191-23-002976#line-1","is_derivative":false,"issuer_cik":"0001434316","issuer_name":"FATE THERAPEUTICS INC","issuer_ticker":"FATE","issuer_name_source":null,"issuer_url":"/issuer/0001434316","owner_cik":"0001868719","owner_name":"Plavsic Mark","owner_display_name":"Plavsic Mark","owner_url":"/insider/0001868719","role":"Officer (Chief Technical Officer)","role_mark":"O","role_mark_label":"Officer (Chief Technical Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Technical Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3418.0,"shares_display":"3,418","price_per_share":5.24,"price_display":"5.24","price_state":"stated","total_value":17910.32,"total_display":"17,910.32","total_whole":"17,910","shares_owned_after":123705.0,"shares_owned_after_display":"123,705","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-01-10","filed_date":"2023-01-11","scope":"insider"},{"id":6185025,"accession":"0001209191-22-041053","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-22-041053","line_url":"/filing/0001209191-22-041053#line-1","is_derivative":false,"issuer_cik":"0001434316","issuer_name":"FATE THERAPEUTICS INC","issuer_ticker":"FATE","issuer_name_source":null,"issuer_url":"/issuer/0001434316","owner_cik":"0001868719","owner_name":"Plavsic Mark","owner_display_name":"Plavsic Mark","owner_url":"/insider/0001868719","role":"Officer (Chief Technical Officer)","role_mark":"O","role_mark_label":"Officer (Chief Technical Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Technical Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3719.0,"shares_display":"3,719","price_per_share":24.61,"price_display":"24.61","price_state":"stated","total_value":91524.59,"total_display":"91,524.59","total_whole":"91,525","shares_owned_after":127123.0,"shares_owned_after_display":"127,123","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-07-05","filed_date":"2022-07-06","scope":"insider"}],"collapsed":true,"next_cursor":null,"ledger_fault":false,"count":{"value":6,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":0,"open_market":true},{"code":"S","label":"Open-market sale","n":6,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":6},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001501796","name":"Aura Biosciences, Inc.","url":"/issuer/0001501796","role":"Officer (Chief Technology Officer)","n_filings":4,"first_seen":"2024-10-16","last_seen":"2026-02-17"},{"type":"issuer","type_label":"ISSUER","cik":"0001434316","name":"FATE THERAPEUTICS INC","url":"/issuer/0001434316","role":"Officer (Chief Technical Officer)","n_filings":2,"first_seen":"2022-07-06","last_seen":"2023-01-11"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001868719","retrieved_at":"2026-08-23T19:30:46+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-21","last_ingest":"2026-08-22T05:23:40.159918+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}